Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United Kingdom
/
Pharmaceuticals & Biotech
Create a narrative
hVIVO Community
AIM:HVO Community
3
Narratives
written by author
0
Comments
on narratives written by author
28
Fair Values set
on narratives written by author
Community Investing Ideas
hVIVO
Popular
Undervalued
Overvalued
hVIVO
AN
AnalystHighTarget
Consensus Narrative from 8 Analysts
FDA Openness And Pandemic Preparedness Will Fuel Expansion
Key Takeaways Industry-leading automation and digital integration could drive greater margin expansion and cost efficiency than analysts expect as the business scales. Strong market positioning, regulatory shifts, and data asset commercialization may yield outsized, sustainable revenue growth and high-margin opportunities.
View narrative
UK£0.37
FV
72.3% undervalued
intrinsic discount
12.91%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
hVIVO
AN
AnalystLowTarget
Consensus Narrative from 8 Analysts
Digital Trials Will Undercut Human Challenge Models But Hope Remains
Key Takeaways Rising digital and decentralized trial adoption, regulatory pressures, and industry cost-cutting threaten hVIVO's traditional market and could compress margins over time. Heavy exposure to niche markets and early-phase biotech clients increases revenue volatility and risk if client demand falters or consolidates.
View narrative
UK£0.17
FV
39.7% undervalued
intrinsic discount
-2.25%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 1 month ago
author updated this narrative
hVIVO
AN
AnalystConsensusTarget
Consensus Narrative from 8 Analysts
Canary Wharf Expansion And Automation Will Improve Efficiency Despite Risks
Key Takeaways hVIVO's operational enhancements and facility expansions aim to boost efficiency and trial capacity, potentially driving revenue and margin growth. Diversification and strategic integrations are set to enhance service offerings, reduce dependency, and strengthen long-term revenue opportunities.
View narrative
UK£0.23
FV
55.9% undervalued
intrinsic discount
1.77%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
16
users have followed this narrative
2 days ago
author updated this narrative
Your Valuation for
HVO
HVO
hVIVO
Your Fair Value
UK£
Current Price
UK£0.10
7.9% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-11m
88m
2015
2018
2021
2024
2025
2027
2030
Revenue UK£88.2m
Earnings UK£14.2m
Advanced
Set Fair Value